Viral Vectors

Companies Viral Vectors

Synplogen Co., Ltd., Japan

Synplogen is a DNA synthesis startup spun out of Kobe University's Graduate School of Science, Technology and Innovation in February, 2017. Combining its proprietary OGAB techniques with cutting edge genetic engineering, information science and robotics, Synplogen provides a variety of services incl more

Nouscom AG, Switzerland

Nouscom is a private oncology company developing next generation immunotherapies. Nouscom's proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Nouscom is led by an exper more

Topas Therapeutics GmbH, Germany

Topas Therapeutics GmbH is a clinical-stage biotechnology company focused on developing novel treatments in areas where patients are in need of more effective options, including autoimmune diseases, allergies and anti-drug immune responses. The Topas Particle Conjugates platform induces antigen-spec more

News Viral Vectors

• Merck and Japanese start-up launch collaboration
  

  Merck has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation. Both companies aim to integrate their capabilities to provide streamlined development, manufacturing and testing for viral v more

• New gene taxis to combat liver disease
  

  There are numerous severe, hardly treatable monogenetic diseases that are caused by a defect in a single gene - also in the liver. These include the blood coagulation disorders haemophilia A or B or the metabolic disease phenylketonuria. Gene therapies could help here, in which intact genes are tran more

• ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
  

  ViGeneron GmbH, a next-generation gene therapy start up, announced a follow-on collaboration with Daiichi Sankyo Company, Limited to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases. more

White papers Viral Vectors

• Adapting the Power of Density Gradient Separations for Gene Therapy Analytics
  

  DGE-AUC is a versatile, thermodynamics driven analytical method based on well known foundational understanding of CsCl density gradients more